“Premji Invest has been an early supporter of Bicara from the beginning, having participated in both our Series A and recent Series B financing. With their support, Bicara is moving forward with urgency towards delivering potential new treatment options to patients struggling with head and neck cancers.”
Claire Mazumdar
CEO, Bicara Therapeutics Inc.
Perspectives
Perspectives
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
Bicara
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
Perspectives
Bicara Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference
Bicara
Bicara Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference
Perspectives
Announces Oversubscribed $165 Million Series C Financing
Bicara Therapeutics
Announces Oversubscribed $165 Million Series C Financing
Perspectives
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
Bicara Therapeutics
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
Perspectives
First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Bicara Therapeutics